Lazertinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Lazertinib. Educational only — not medical advice.
Labeled uses
LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] .
Source: FDA labeling via NIH DailyMed (set c417f9ee…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.